
Geovax Labs (GOVX) Stock Forecast & Price Target
Geovax Labs (GOVX) Analyst Ratings
Bulls say
Geovax Labs is well-positioned for future success with multiple potential catalysts on the horizon, including progress towards clinical execution of GEO-MVA and the initiation of a Phase 2 trial for Gedeptin in combination with an immune checkpoint inhibitor. Additionally, the distinctive attributes of its GEO-CM04S1 COVID-19 vaccine, such as targeting multiple antigens, make it a desirable candidate for commercialization in immunocompromised and high-risk populations. Despite reporting a decline in revenue and net loss for 2025, the company's strong focus on R&D and cost management highlights its commitment to advancing its innovative pipeline and achieving its ultimate goal of bringing novel treatments to market.
Bears say
Geovax Labs is facing a constrained near-term outlook due to limited near-term catalysts and tightening capital resources, prompting a downgrade from Buy to Hold. While the company has a strong focus on developing MVA-based vaccines for infectious diseases and solid tumor cancers, the potential value realization for these programs is delayed, with targeted data not expected until 2027. Furthermore, with a low cash balance and recent $1M financing, the company may face heightened dilution risk in the future, making it a risky investment in the short term.
This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.
Geovax Labs (GOVX) Analyst Forecast & Price Prediction
Start investing in Geovax Labs (GOVX)
Order type
Buy in
Order amount
Est. shares
0 shares